BridgeMD

Sign in

Mesothelioma clinical trials

Explore recruiting mesothelioma clinical trials.

Recruiting mesothelioma studies right now

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mesothelioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

IFCT-2403 BI-MAPS Assessment of ivonescimab as salvage treatment in relapsing pleural mesothelioma patients, previously treated by immunotherapy and standard chemotherapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Mesothelioma trials by city

Mesothelioma in Toronto Mesothelioma in Vancouver Mesothelioma in Montreal Mesothelioma in Calgary Mesothelioma in Edmonton Mesothelioma in Ottawa Mesothelioma in Winnipeg Mesothelioma in Quebec City Mesothelioma in Hamilton Mesothelioma in Kitchener Mesothelioma in London Mesothelioma in Halifax Mesothelioma in New York Mesothelioma in Los Angeles Mesothelioma in Chicago Mesothelioma in Houston